השוואת שיטות

	שאלון איכות חיים באקנה (Acne-QoL)	MelasQoL (סולם איכות חיים של מלזמה)	POEM (מדד ממוקד-מטופל לאקזמה)
תחום	דרמטולוגיה	דרמטולוגיה	דרמטולוגיה
משפחה	Process / pipeline	Process / pipeline	Process / pipeline
שנת המקור	2004	2006	2004
הוגה השיטה	Halvorsen JA et al.	Cestari TF, Hexsel D	Charman CR, Venn AJ, Williams HC
סוג	Self-report	Self-report	Self-report
מקור מכונן	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.
כינויים	Acne-Q, Acne-Specific QoL	Melasma-QoL	POEM Score
קשורות	4	3	2
תקציר	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.